
'Color is not just something we see'
2025 Color and Design Seminar sheds light on the influence of color in various aspects of life
Color is not just something we see. It is more than a visual experience and plays a crucial role in design and branding.
This was the idea discussed at the 2025 Color and Design Seminar held at JW Marriott Dongdaemun Square on Wednesday as experts gathered to shed light on the influence of color in various aspects of life and industries.
Ora Solomon, vice president of product and engineering at Pantone, highlighted that color is a powerful branding tool for creating a strong brand identity and connecting with consumers. Pantone is a US-based consulting service that forecasts global color trends dubbed "Color of the Year" and advises companies on colors for brand identity and product development.
"Someone once said, 'Color is a story for life.' It can help you differentiate, as well as communicate and connect to a specific audience," she explained.
"It's a silent brand ambassador who speaks without saying any word and has the power to evoke emotions, convey meaning and create a lasting impression of the brand, whether through graphics, product design, or packaging that helps your products stand out on a busy shelf," Solomon added. In fact, nearly 85 percent of all purchase decisions are driven by color, while up to 87 percent of brand recognition comes from color, according to a study by Pantone.
Solomon also highlighted the importance of integrating the physical and digital worlds using color for better aesthetic outcomes and allowing colors to resonate with customers.
For example, Pantone collaborated with Porsche to develop "Turbonite," a signature color for all Turbo models. Introduced in 2023, this elegant metallic grey features a tawny bronze undertone, reflecting Porsche's legacy of history and innovation. Last year, Pantone came up with Mediterranean Riviera-inspired colors that evoked the idea of "endless summer" when Nespresso sought help to drive its sales during the summer months, according to Solomon.
"The first thing that we typically see as consumers -- not necessarily as designers or business people -- is color, and the beauty of color is that it connects with you," Solomon said.
Lily Tsai, a senior color technologist at BenQ -- a Taiwanese multinational technology company ensuring the best color performance in visual products -- underscored the importance of addressing color differences and ensuring color accuracy to deliver high-quality visual communication.
"Sometimes the colors on your monitors, camera, scanner and when you print all look different. Which one should you trust? ... Well, color management can solve that problem," Tsai said. Color management is the method used to ensure that colors remain consistent across different devices and formats.
"Just like how we maintain our car to ensure driving safety, calibrating your monitor in the same way helps get the reliable color you want. This also makes your work much more convenient."
As much as how color has become pivotal in design, guiding perceptions and influencing emotions, Shin Ye-soo, a solution consultant at Adobe, pointed out that digital tools have also advanced, allowing users to create a shade of their choice.
For example, users can apply color changes by entering a specific code using Adobe Firefly -- a generative AI-powered tool that lets you create images from text descriptions.
"Digital tools like Adobe Firefly can now generate nearly an infinite variety of colors and textures. It also makes combining multiple colors easier, giving users more flexibility and control over their work," Shin said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Korea Herald
2 hours ago
- Korea Herald
ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore
SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedTech ventures in Singapore. This partnership will support venture creation, product development, and commercialisation by bringing together ClavystBio and two national initiatives hosted by A*STAR — MedTech Catapult and the Diagnostics Development Hub (DxD Hub) — along with A*STAR's broader MedTech and venture creation capabilities. The partnership comes amid growing momentum in Singapore's biomedical landscape, with MedTech output reaching S$20 billion in 2023. [1] As Asia's MedTech market is projected to grow to US$225 billion (S$304 billion) by 2030, [2] these efforts aim to better position Singapore-based innovations to scale and enter new markets. Over this two-year partnership, the parties will work towards the co-creation of new MedTech ventures, investments into A*STAR affiliated companies, and fostering collaborations between A*STAR and ClavystBio's portfolio companies. By combining complementary strengths — from research and engineering to venture building and funding — the partnership aims to identify promising technologies, shape MedTech projects for market readiness, and support new venture formation to strengthen Singapore's innovation-driven MedTech ecosystem. The partnership will focus on several key areas: "This partnership highlights ClavystBio's commitment to nurturing globally successful medical devices, digital health, and diagnostics companies from Singapore," said Mr Anselm Tan, Digital Health & MedTech Lead at ClavystBio. "By combining ClavystBio's investment and venture-building expertise with A*STAR's deep scientific capabilities and productisation platforms, we are cultivating an ecosystem primed for innovation and commercial success. "A*STAR is committed to nurturing a dynamic MedTech ecosystem that bridges innovation with deep tech companies," said Ms Irene Cheong, Assistant Chief Executive (Innovation & Enterprise) at A*STAR. "This MoU builds on an existing collaboration with ClavystBio and marks a significant step forward in our joint efforts to co-create and grow globally investible MedTech ventures. Through national productisation platforms like MedTech Catapult and DxD Hub, combined with A*STAR's venture creation capabilities, we aim to commercialise more innovations from lab to market and grow a vibrant MedTech ecosystem in Singapore." About ClavystBio ClavystBio is a life sciences investor and venture builder set up by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing start-ups together, we foster a vibrant and supportive community. About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit About Diagnostics Development Hub (DxD Hub) The Diagnostics Development Hub is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub aims to accelerate the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption. Through impactful products, empowering local enterprises and anchoring global companies in Singapore, DxD Hub contributes to the development of an effective diagnostic devices' ecosystem in Singapore. For ongoing news, visit About MedTech Catapult MedTech Catapult (MC) is a national initiative designed to accelerate the product development and commercialisation of high-value life science instruments and regulated medical devices. MC partners with product owners, local contract manufacturers (CMs), and leverages external design houses, and other key stakeholders to guide innovations from concept to market. Their goal is to strengthen Singapore's medtech ecosystem by providing dedicated engineering, quality assurance, regulatory affairs, clinical affairs, project management and commercialisation support to derisk and support products towards commercialisation and market adoption whilst supporting pull-through to local manufacturing.


Korea Herald
3 hours ago
- Korea Herald
Posco Future M advances supply chain independence with new precursor plant
Facility aims to meet rising demand for China-independent battery materials amid shifting US trade policies Korean battery material manufacturer Posco Future M officially opened its new precursor plant Tuesday in Gwangyang, South Jeolla Province, marking a key step in its efforts to build a self-sufficient supply chain. 'The completion of this precursor plant, following Posco Group's establishment of its own nickel supply chain, marks the realization of a fully self-sufficient system, from raw materials to intermediate products and the finished cathode material,' said Eom Gi-chen, CEO of Posco Future M, during the opening ceremony. 'In today's rapidly changing global supply chain landscape, the Gwangyang precursor plant will enhance the competitiveness and growth of Korea's battery industry.' The 22,400 square meter facility has an annual production capacity of 45,000 metric tons of precursor — a chemically synthesized mixture of metals used in cathode materials — enough to support battery production for 500,000 electric vehicles, the company said. The facility, which has been ramping up operations since May, was largely in operation during a media tour held the same day. The plant was filled with around 50 large metal tanks spread across the factory floor. The precursor production process involves six main steps: dissolving metals in purified water, inducing chemical reactions with catalysts to form precursor crystals, then washing, dehydrating, drying and packaging the final product. 'The reaction process is the core of precursor manufacturing, as it determines the material's density and elemental ratio, both of which are tailored to meet customer specifications,' a company official said, noting Posco Future M's flexibility in adjusting compositions to client needs. Currently, the company uses nickel, cobalt and manganese to produce precursors for NCM cathodes used in electric vehicle batteries, according to the order by Ultium Cells, a US-based 50:50 joint venture between LG Energy Solution and General Motors. 'All precursors produced at this facility are currently supplied to Ultium Cells,' the official added. The company said the timely launch was driven by growing demand from customers for China-independent supply chains, while many other battery projects have been delayed amid sluggish EV demand. The US Inflation Reduction Act disqualifies EV batteries containing materials from 'foreign entities of concern,' including China, from tax credit eligibility. This policy shift has prompted automakers to reduce reliance on Chinese suppliers, who currently dominate 90 percent of the global precursor market. To meet these evolving demands, Posco Future M said it has also secured alternative sources for raw materials used in precursor production. 'We understand the risks automakers face when their supply chains are overly concentrated in China. Regardless of cost considerations, that's where the competitiveness of our plant comes in,' said Lee So-young, head of the business strategy planning group at Posco Future M. 'As US policies continue to evolve, we're working to establish a supply chain that's less exposed to such changes, including sourcing raw materials independently of Chinese suppliers.' The plant's 10 production lines are controlled by about 10 staff members via monitors that provide a real-time overview of the process. With a high degree of automation, the company aims to enhance quality control of its cathod materials — a factor it says was more difficult to achieve when using externally sourced precursors. 'When customers request specific features, many of them cannot be achieved simply by processing third-party precursors,' Lee added. 'We believe our ability to meet those demands in both quality and cost also gives us a key competitive edge.'


Korea Herald
7 hours ago
- Korea Herald
Hanwha wins US approval to acquire stake in Australia-based shipbuilder Austal
South Korea's Hanwha Group said Tuesday it has received approval from the US government to acquire up to a 100 percent stake in Australia-based shipbuilding and defense firm Austal, clearing a major hurdle in its push to expand its presence in the global defense market. The recent approval from the Committee on Foreign Investment in the United States (CFIUS) allows Hanwha to increase its current 9.9 percent stake in Austal to full ownership, the group said. Hanwha had initially filed for CFIUS to approve a 19.9 percent stake acquisition. CFIUS is an interagency committee of the US government that reviews the national security implications of foreign investments in US companies. Austal operates a major US naval shipyard in the United States. The committee said there were no unresolved national security concerns with the deal, effectively recognizing the legitimacy of Hanwha's acquisition bid, the South Korean group said. Hanwha first purchased a 9.9 percent stake in Austal in March and has since sought approvals from both the Australian and US governments to increase its holdings to 19.9 percent. Headquartered in Australia, Austal is a global defense shipbuilder with major operations in the US, supplying vessels to the US Navy. Hanwha said it plans to leverage its shipbuilding capabilities to boost Austal's global competitiveness while seeking to expand joint business opportunities in both the US and Australian defense markets. (Yonhap)